| Assessment Status | Rapid Review Complete |
| HTA ID | 23039 |
| Drug | Atogepant |
| Brand | Aquipta® |
| Indication | Prophylaxis of migraine in adults who have at least 4 migraine days per month |
| Assessment Process | |
| Rapid review commissioned | 10/07/2023 |
| Rapid review completed | 21/08/2023 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atogepant for this indication on the basis of the proposed price relative to currently available therapies. * |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
